Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hand-foot-skin reaction in sorafenib therapy for hepatocellular carcinoma

Trial Profile

Hand-foot-skin reaction in sorafenib therapy for hepatocellular carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2018

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Jul 2018 New trial record
    • 18 Jul 2018 Results published in the Investigational New Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top